Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | CCR3 | P51677 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3779383 | 0.91 | KMT2A (0.52) | KMT2ASIGMAR1MEN1CCR3KDM4E | |
| SCHEMBL3767678 | 0.89 | KMT2A (0.53) | KMT2ASIGMAR1MEN1CCR3KDM4E | |
| SCHEMBL3774296 | 0.87 | KDM4E (0.53) | KMT2ASIGMAR1MEN1CCR3KDM4E | |
| SCHEMBL3767508 | 0.86 | KDM4E (0.49) | KMT2ASIGMAR1MEN1CCR3KDM4E | |
| SCHEMBL3774233 | 0.86 | RAB9A (0.57) | KMT2ASIGMAR1MEN1KDM4EALDH1A1 | |
| SCHEMBL3780644 | 0.86 | ALDH1A1 (0.55) | KMT2ASIGMAR1MEN1KDM4EALDH1A1 | |
| SCHEMBL3775648 | 0.85 | KDM4E (0.57) | KMT2ASIGMAR1MEN1CCR3KDM4E | |
| SCHEMBL3773681 | 0.85 | KDM4E (0.55) | KMT2ASIGMAR1MEN1CCR3KDM4E | |
| SCHEMBL3772003 | 0.85 | CCR3 (0.55) | KMT2AMEN1CCR3KDM4EALDH1A1 | |
| SCHEMBL3776056 | 0.85 | KMT2A (0.57) | KMT2AMEN1KDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | KMT2A 242/4885SIGMAR1 505/4885MEN1 3270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.